Inpatient, Outpatient, and Pharmacy Costs in Patients With and Without HIV in the US Veteran's Affairs Administration System
- PMID: 31213120
- PMCID: PMC6748482
- DOI: 10.1177/2325958219855377
Inpatient, Outpatient, and Pharmacy Costs in Patients With and Without HIV in the US Veteran's Affairs Administration System
Abstract
Objectives: To evaluate the association between human immunodeficiency virus (HIV) patients and medical costs (inpatient, outpatient, pharmacy, total) using a national cohort of HIV-infected Veterans and non-HIV matched controls within the Veteran's Affairs (VA) Administration system.
Design: This study used claims (January 2000 to December 2016) extracted from the VA Informatics and Computing Infrastructure and VA Health Economics Resource Center. Cases included Veterans with an International Classification of Diseases, Ninth Revision/International Classification of Diseases, Tenth Revision for HIV with at least 1 prescription for a complete antiretroviral therapy regimen (January 2000 to September 2016). Two non-HIV controls were exact matched on race, sex, month, and year of birth. All patients were followed until the earliest of the following: last date of VA activity, death, or December 31, 2016.
Results: A total of 79 578 patients (26 526 HIV and 53 052 non-HIV) met all study criteria. The average age was 49.3 years, 38% were black, 32% were white, and 97% were male for both the HIV and control cohorts. Adjusted multivariable logistic regression models demonstrated that HIV was associated with higher odds of incurring a pharmacy cost (odds ratio = 2286.45, 95% confidence interval: 322.79-16 195.82), 4-fold, and 2-fold higher odds of incurring both outpatient and inpatient costs compared to the matched controls, respectively. In adjusted multivariable gamma generalized linear models, HIV-positive patients had an almost 4-fold, 17-fold, and almost 2-fold higher cost than matched controls in total, pharmacy, and outpatient costs, respectively.
Conclusions: This study found an association between HIV-positive patients having higher odds of incurring a medical cost as well as higher medical costs compared to non-HIV controls.
Keywords: HIV; inpatient costs; outpatient costs; pharmacy costs.
Conflict of interest statement
Similar articles
-
Chronic kidney disease, cardiovascular disease, and osteoporotic fractures in patients with and without HIV in the US Veteran's Affairs Administration System.Curr Med Res Opin. 2019 Jan;35(1):117-125. doi: 10.1080/03007995.2018.1543183. Epub 2018 Nov 13. Curr Med Res Opin. 2019. PMID: 30378450
-
Decreased medical expenditures for care of HIV-seropositive patients. The impact of highly active antiretroviral therapy at a US Veterans Affairs Medical Center.Pharmacoeconomics. 1999 Sep;16(3):307-15. doi: 10.2165/00019053-199916030-00007. Pharmacoeconomics. 1999. PMID: 10558042 Clinical Trial.
-
Utilization and expenditures of veterans obtaining primary care in community clinics and VA medical centers: an observational cohort study.BMC Health Serv Res. 2007 Apr 18;7:56. doi: 10.1186/1472-6963-7-56. BMC Health Serv Res. 2007. PMID: 17442115 Free PMC article.
-
[Cost of HIV treatment in highly active antiretroviral therapy in Japan].Nihon Rinsho. 2002 Apr;60(4):813-6. Nihon Rinsho. 2002. PMID: 11968794 Review. Japanese.
-
The lifetime cost of current human immunodeficiency virus care in the United States.Med Care. 2006 Nov;44(11):990-7. doi: 10.1097/01.mlr.0000228021.89490.2a. Med Care. 2006. PMID: 17063130 Review.
Cited by
-
Economic Burden of HIV in a Commercially Insured Population in the United States.J Health Econ Outcomes Res. 2023 Jan 19;10(1):10-19. doi: 10.36469/001c.56928. eCollection 2023. J Health Econ Outcomes Res. 2023. PMID: 36721765 Free PMC article.
-
The price of progress: Assessing the financial costs of HIV/AIDS management in East Africa.Medicine (Baltimore). 2025 May 2;104(18):e42300. doi: 10.1097/MD.0000000000042300. Medicine (Baltimore). 2025. PMID: 40324279 Free PMC article. Review.
-
Real-World Assessment of Weight Change in People with HIV-1 After Initiating Integrase Strand Transfer Inhibitors or Protease Inhibitors.J Health Econ Outcomes Res. 2020 Jul 16;7(2):102-110. doi: 10.36469/jheor.2020.13457. eCollection 2020. J Health Econ Outcomes Res. 2020. PMID: 32766375 Free PMC article.
-
Estimation of Lifetime Costs Among Insured Persons with HIV in the United States.Pharmacoecon Open. 2025 Jun 9. doi: 10.1007/s41669-025-00584-0. Online ahead of print. Pharmacoecon Open. 2025. PMID: 40490607
References
-
- CDC. CDC Fact Sheet: Trends in U.S. HIV Diagnoses, 2005-2014. https://www.cdc.gov/nchhstp/newsroom/docs/factsheets/hiv-data-trends-fac.... Accessed July 1, 2017.
-
- HIV.gov. HIV Basics Overview: Data and Trends: U.S. Statistics. https://www.hiv.gov/hiv-basics/overview/data-and-trends/statistics. Published 2017. Accessed May 29, 2018.
-
- Hogg RS, Heath K V, Yip B, et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA. 1998;279(6):450–454. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous